The U.S. Food Drug Administration allow ICN Pharmaceuticals Inc resume test ribavirin experimental AIDS drug accord ICN. "Our safety concern sufficient magnitude withhold approval far clinical study design ass safety efficacy ribavirin" FDA told ICN Chairman Milan Panic October 16 letter ICN. An FDA spokesman confirm authenticity letter. ICN's test drug human block spring FDA decide insufficient evidence effectiveness common AIDS-related conditions. The test intend determine whether ribavirin effective AIDS-Related Complex (ARC) Lymphadenopathy Syndrome LAS. FDA Commissioner Frank Young disclose May agency investigate "suspicious" test result submit ICN antiviral drug. Young personally scold ICN official make exaggerated claim drug. In addition House subcommittee probe ICN trading financial irregularities. Today FDA let ICN test ribavirin safety effectiveness 32 patient ARC LAS. Reuter 